Approval · Notice of Compliance 36982 · 2026
LONGAVO: Notice of Compliance 36982
Issued February 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36982
- Date
- February 25, 2026
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the manufacturing process for the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LONGAVO | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 125 MG per 0.35ML
- RISPERIDONE 100 MG per 0.28ML
- RISPERIDONE 75 MG per 0.21ML
- RISPERIDONE 50 MG per 0.14ML